print_label | resize_label

Start Onglyza for glucose control with confidence

Click here to view the Onglyza Product Information

Start Komboglyze for glucose control with confidence

Click here to view the Komboglyze Product Information

Explore saxagliptin’s key clinical data and test your knowledge

View interactive clinical summary

Experience in NYHA class III–IV is still limited. Therefore, caution is warranted in these patients. In the SAVOR trial, a small increase in the rate for hospitalisation for heart failure, occurred at a greater rate in Onglyza-treated patients (3.5%) compared with placebo (2.8%; p=0.007). There was no imbalance in CV deaths due to heart failure (0.5% in each group according to 2-year Kaplan-Meier estimates). Additional analysis did not indicate a differential effect among NYHA classes.1

Komboglyze should not be used in patients with acute or chronic disease which may cause hypoxia, such as cardiac or respiratory failure, recent MI or shock.5

The right product for the right patient

Use our patient profiler to understand the differences between our products.

View patient profiler


About Onglyza

Onglyza (saxagliptin) is a DPP-4 inhibitor that is approved for use as monotherapy or add-on therapy1


Onglyza delivers comparable HbA1c reductions to a SU, with fewer hypoglycaemic events and no weight gain2,3

SAVOR CV outcomes trial

Onglyza's CV safety profile demonstrated in a broad spectrum of high-CV-risk patients4

About Komboglyze

Komboglyze is a fixed-dose combination therapy containing saxagliptin (a DPP-4 inhibitor) and metformin in a single tablet


The combination of saxagliptin + metformin delivers similar HbA1c reductions to a SU + metformin, with fewer treatment concerns2,3,5

Safety and tolerability profiles

Saxagliptin + metformin is generally well tolerated, with a comparable adverse-event profile versus placebo, and reduced gastrointestinal effects compared with metformin alone5